new drug to fight against localized highrisk prostate tumors
Last Updated : GMT 06:49:16
Arab Today, arab today
Arab Today, arab today
Last Updated : GMT 06:49:16
Arab Today, arab today

New drug to fight against localized high-risk prostate tumors

Arab Today, arab today

Arab Today, arab today New drug to fight against localized high-risk prostate tumors

Washington - Arabstoday

Men with prostate cancer could significantly benefit from a recently approved hormone-depleting drug, according to results from a phase II clinical trial. The drug - abiraterone acetate (Zytiga(R)) - can help eliminate or almost eliminate tumors in many prostate cancer patients whose cancer has not yet metastasized. The study, conducted by researchers at Dana-Farber Cancer Institute in collaboration with other research centers, will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO), June 1-5, in Chicago. In order to examine the effects of (Zytiga(R)) in combination with prednisone and surgery, the researchers enrolled 58 men with high-risk prostate cancer isolated to the prostate gland to participate in the study. Study participants were assigned to receive the combination therapy for either three or six months, in addition to surgery to remove the prostate. After completing the treatment regimen, the researchers found that one-third of the men had either little or no tumor tissue left. Mary-Ellen Taplin, M.D., of Dana-Farber, and lead author of the study, said: "Very high-risk cancers localized to the prostate are rarely cured by prostatectomy alone. Therapies that combine surgery with older androgen-inhibiting drugs have not historically improved outcomes. This unmet need has given rise to efforts to develop new drugs capable of more completely reducing androgen levels within the prostate tumors." The male hormone androgen powers prostate cancer growth, and although standard treatments target the production of this hormone in the adrenal glands and testes, they do not target androgen within the tumor itself. However, abiraterone acetate has the ability to inhibit the production of androgen in all three sites. In addition to abiraterone acetate, study participants also received 5mg daily of prednisone (a steroid). Conventionally, prednisone is administered with abiraterone acetate in a 10mg dose. However, the researchers believed that the lower dose would reduce the adverse effects of prednisone while maintaining its benefits. According to the researchers, the 5mg dose is adequate for the majority of patients. Taplin explained: "Most of the patients in this study had large tumors, high grade prostate cancers and were at high risk for cancer spread. We're very encouraged by the results and have begun another phase II study investigating another novel androgen signaling inhibitor, MDV3100, in the neoadjuvant setting for high risk prostate cancer. We are also developing a clinical trial program investigating the addition of the investigational drug ARN509 to abiraterone. To prove the overall benefit of intensive androgen deprivation treatment in conjunction with prostatectomy, a large randomized clinical trial will need to be done."

arabstoday
arabstoday

Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

new drug to fight against localized highrisk prostate tumors new drug to fight against localized highrisk prostate tumors

 



Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

new drug to fight against localized highrisk prostate tumors new drug to fight against localized highrisk prostate tumors

 



GMT 14:30 2017 Sunday ,22 October

Abe coalition wins resounding victory in Japan vote

GMT 09:44 2017 Tuesday ,17 October

Morocco arrests 11 suspects linked to ISIS

GMT 13:09 2015 Tuesday ,09 June

Slaven Bilic returns to West Ham as manager

GMT 16:04 2017 Saturday ,30 September

Got a yacht? Proposed French tax break makes waves

GMT 13:06 2016 Saturday ,31 December

Syrian passport trade becomes unlikely cash cow

GMT 04:47 2017 Wednesday ,30 August

Mark Zuckerberg welcomes second daughter in Facebook

GMT 00:59 2014 Saturday ,07 June

January 19 - February 17

GMT 10:53 2017 Wednesday ,05 July

AU Summit gives priority to youth empowerment

GMT 17:26 2017 Wednesday ,15 February

Russian jets in ‘unsafe’ encounters with destroyer
Arab Today, arab today
 
 Arab Today Facebook,arab today facebook  Arab Today Twitter,arab today twitter Arab Today Rss,arab today rss  Arab Today Youtube,arab today youtube  Arab Today Youtube,arab today youtube

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©

arabstoday arabstoday arabstoday arabstoday
arabstoday arabstoday arabstoday
arabstoday
بناية النخيل - رأس النبع _ خلف السفارة الفرنسية _بيروت - لبنان
arabstoday, Arabstoday, Arabstoday